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Abstract: 36 
Background: 37 
Uterine sarcomas are a group of mesenchymal tumours comprising several 38 
histologies. They have a high recurrence rate following surgery, modest 39 
outcome to systemic therapy, and poor overall survival.  Pazopanib is a multi-40 
targeted tyrosine kinase inhibitor approved for non-adipocytic advanced soft 41 
tissue sarcomas (STS). Here we investigated whether response to pazopanib 42 
in patients with uterine sarcomas differs from that of patients with non-uterine 43 
sarcomas. 44 
Patients and methods:  Uterine sarcoma patients were retrieved from all soft 45 
tissue sarcoma patients treated with pazopanib in EORTC Phase II (n=10) 46 
and Phase III (PALETTE) (n=34) studies. Patient and tumour characteristics, 47 
response, progression free and overall survival data were compared. 48 
Results: Forty-four patients with uterine sarcoma were treated with pazopanib. 49 
The majority of patients had uterine leiomyosarcoma (LMS) (n = 39, 88.6%) 50 
with high grade tumours (n= 37, 84.1%) compared to 54.8% (n=164) in the 51 
non-uterine population. The median age was 55 years (range 33-79) and 52 
median follow up was 2.3 years. Uterine patients were heavily pre-treated, 53 
61.3% having ≥ 2 lines of chemotherapy prior to pazopanib compared to 54 
40.8% in the non-uterine population. Five patients (11%), all LMS, had a 55 
partial response ( 95% CI 3.8-24.6).  Median progression free survival (PFS) 56 
3.0 months (95% CI 2.5.-4.7) in uterine versus 4.5 (95% CI 3.7-5.1) in non-57 
uterine STS.  Median overall survival (OS) was 17.5 months (95% CI 11.1-58 
19.6), longer than the non-uterine population, 11.1 months (95% CI 10.2-12.0) 59 
(p=0.352).  60 
 4 
Conclusions: Despite heavy pre-treatment, pazopanib shows signs of activity 61 
in patients with uterine sarcoma with the similar outcomes to patients with 62 
non-uterine STS. 63 
 64 
 65 
 66 
 67 
68 
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Full manuscript body text 69 
Introduction 70 
Uterine sarcomas are a rare and heterogeneous group of mesenchymal 71 
tumours that account for up to 5% of all uterine body malignancies. (1) 72 
Leiomyosarcoma (LMS) is the most common histological subtype comprising 73 
63% in one series followed by endometrial stromal sarcoma (ESS) (21%), 74 
undifferentiated endometrial sarcoma (6%), with adenosarcoma and other 75 
rare subtypes making up the remainder. (2). Surgery is the mainstay of 76 
treatment in early stage disease whatever the histological subtype (3). 77 
However, recurrence rates are high. For example, in completely resected 78 
FIGO stage 1b uterine LMS 55% of patients relapse (4). In patients with 79 
advanced or locally recurrent disease, palliative systemic treatment can be 80 
considered. As holds true for all soft tissue sarcomas, outcomes to systemic 81 
treatment greatly differ across the different subtypes. Of all the uterine 82 
sarcomas uterine LMS is the most chemo-sensitive (5). In advanced disease, 83 
active agents in uterine LMS include doxorubicin, gemcitabine combined with 84 
docetaxel or gemcitabine alone, trabectedin and dacarbazine (6) However, 85 
response rates are typically modest, ranging from 10-36% and are of relatively 86 
short duration, with a median PFS of around 4 months (5). Patients with low 87 
grade ESS exhibit a more indolent disease pattern and are sensitive to 88 
hormonal manipulation with aromatase inhibitors (7) (8). In contrast, those 89 
patients with high grade undifferentiated uterine sarcoma have a particularly 90 
poor prognosis with a paucity of active agents in this disease type (9)(10). 91 
Given the median overall survival for all patients advanced uterine soft tissue 92 
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sarcoma (STS) remains in the order of 10 months there is a pressing need for 93 
new therapies. (5) 94 
 95 
Anti-angiogenic approaches have been explored in patients with uterine LMS. 96 
A clinical trial of sunitinib revealed responses in 2 out of 23 patients with 97 
uterine LMS, failing to meet pre-defined criteria to warrant further examination 98 
(11)(12). The addition of bevacizumab to gemcitabine and docetaxel 99 
chemotherapy was also initially investigated in STS including those with 100 
uterine LMS where the toxicity of this regimen was relatively high. (13) 101 
Furthermore, a subsequent randomized, placebo controlled Phase III trial of 102 
gemcitabine, docetaxel +/- bevacizumab in patients with metastatic uterine 103 
LMS was stopped early due to futility with no improvement in PFS, OS or 104 
response rate (RR)(14). Pazopanib is another compound thought to exert its 105 
anti-tumour activity partially through inhibition of angiogenesis. This drug is a 106 
multi-targeted tyrosine kinase inhibitor which targets not only vascular 107 
endothelial growth factor (VEGFR)-1,-2, and -3 but also platelet- derived 108 
growth factor receptor (PDGFR) –α,-ß and KIT. Clinically relevant responses 109 
in patients with sarcoma were seen in the initial Phase 1 trial.(15) 110 
Subsequently a large stratified EORTC STBSG Phase II trial (62043) of 142 111 
patients was performed which confirmed activity by progression free rate at 12 112 
weeks in three out of four STS groups including the LMS cohort (16). The 113 
Phase III randomised double blind placebo controlled 62072 (PALETTE) study 114 
followed, assigning 369 patients with advanced or metastatic non-adipocytic 115 
STS progressing on previous chemotherapy to either pazopanib or placebo 116 
and a significant increase in PFS of 4.6 months versus 1.6 months was seen. 117 
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(17) On the basis of the trial, pazopanib was approved for non-adipocytic STS 118 
patients failing prior treatment with doxorubicin- and/or ifosfamide-based 119 
chemotherapy. These results were promising for physicians treating uterine 120 
sarcoma patients potentially highlighting a novel treatment pathway. This 121 
paper investigates in detail the outcome of patients with uterine sarcoma 122 
treated with pazopanib in both the Phase II and III EORTC/GSK jointly 123 
sponsored studies. 124 
 125 
 126 
Patients and methods 127 
(i) Patients included: 128 
Patients eligible for this retrospective analysis were those with uterine 129 
sarcoma, included and treated with pazopanib in the Phase II study (n= 10) or 130 
randomized to the pazopanib arm of the Phase III trial (n= 34).  Central  131 
pathological review was performed as per trial protocols. 132 
(Figure 1 Consort diagram) 133 
 134 
(ii) Definition of endpoints: 135 
PFS was defined from the date of registration/randomization to the first 136 
documentation of progression or death, whichever occurred first. The 137 
radiological assessment of the principal investigator was used for the 138 
definition of progression; clinical progression in the absence of documented 139 
objective progression was also taken into account. Patients were censored at 140 
the date of last patient visit (before the clinical cut-off date). OS was defined 141 
as from the date of registration/randomization to the date of death. Patients 142 
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alive at the time of the clinical cut-off were censored at the date of last follow-143 
up. Tumour response was measured by RECIST version 1.1 (18) 144 
  145 
(iii) Statistical analysis: 146 
The characteristics of uterine sarcoma patients were compared to those of the 147 
remaining STS patients receiving treatment in the pazopanib studies using 148 
descriptive tables (patient characteristics, disease characteristics, treatment 149 
exposure, toxicity and post protocol treatment). PFS and OS were estimated 150 
by the Kaplan-Meier method. Statistical significance for OS is based on a 151 
logrank test of the survival of the two subgroups, stratified by study. 152 
Due to the limited number of patients available for this analysis, only 153 
univariate models (logistic regression for best overall response and Cox 154 
regression models for PFS and OS) were used to assess the value of 155 
selected prognostic factors to predict outcome of uterine sarcoma patients 156 
treated with pazopanib. 157 
 158 
 159 
Results 160 
(i) Characteristics 161 
Out of the 343 eligible patients for this analysis,( ie the total number of 162 
patients receiving pazopanib in the Phase II and Phase III trials,) 44 presented 163 
with a uterine sarcoma. The median age was 55 years (range 33-79) in the 164 
uterine population, similar to that of the non-uterine sarcoma patients; the 165 
majority (59.1%) was performance status 1, compared to 48.8% of the non 166 
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uterine soft tissue sarcoma patients. Patient demographics are summarized in 167 
Table 1. 168 
Five patients were treated with pazopanib in the first line metastatic setting 169 
having received anthracycline-based neo-adjuvant chemotherapy previously, 170 
twelve received treatment in the second line, thirteen in the third line, ten in 171 
the fourth and four patients in the fifth line. Compared to the other patients 172 
included, those with uterine sarcoma were more heavily pre-treated with 173 
61.3% having ≥ 2 lines of chemotherapy prior to pazopanib compared to 174 
40.8% of non-uterine patients.   175 
Central pathological review was performed for all patients in the Phase III 176 
study and for all but 23 patients in the Phase II trial, 9 of whom had uterine 177 
sarcoma. Most patients (88.6%) had a diagnosis of uterine LMS and the 178 
majority had high grade tumors (84.1%), compared to 54.8% in non-uterine 179 
STS. The remaining pathological subtypes in the uterine sarcoma group 180 
included one patient with PEComa and one had undifferentiated sarcoma, 181 
three could not be classified further due to insufficient material on central 182 
histological review. No patients with ESS were treated in these studies. 183 
The clinical cut-off dates for this pooled analysis resulted in an overall median 184 
follow-up of 2.3 years (IQR 1.9-2.9).  185 
 186 
(ii) Treatment and response 187 
The median time on treatment  for all uterine sarcoma patients was 14.3 188 
weeks (range 03-135.2 weeks) compared to 17.1 weeks (0.1-191.7 weeks) for 189 
non-uterine STS patients. Two patients with metastatic uterine sarcoma, both 190 
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with LMS, one intermediate and one high grade, were still on pazopanib at the 191 
cut off dates.  192 
Five patients (11.4%) with uterine sarcoma achieved a partial response (PR) 193 
while on treatment with pazopanib with a median duration of 3.9 months ( 194 
range 1.8-9.4 months); twenty-five patients ( 56.8%) had stable disease as 195 
best response with a median duration of 4.7 months (95% CI 3.0 – 8.8). These 196 
response data are comparable to those of the non-uterine sarcoma patients 197 
on pazopanib where 10.7 % of  non-uterine patients achieved a PR and 198 
57.2% stable disease with a median duration of response of 7.5 months . 199 
Of the five patients with PR, four of them received pazopanib in the second 200 
line setting following anthracyline based chemotherapy, one in the third 201 
following anthracycline and gemcitabine/docetaxel. Four of these patients had 202 
high grade uterine LMS and one patient had intermediate grade. The age of 203 
these patients ranged from 33-74y. 204 
 205 
(iii) Toxicity  206 
Treatment related toxicity was similar in the group of uterine patients to that of 207 
the non-uterine patients. Grade 3-4 adverse events while on treatment 208 
included tumour pain (11.4%), fatigue (9.1%) and lymphopenia (11.4%). See 209 
Table 2 for grade 3/4 toxicities. Six  patients ( 14.3%) stopped treatment due 210 
to toxicity related to the study drug. The median time to stopping treatment for 211 
these patients was 41 days (range 2-141 days). The majority of patients 212 
(n=35, 83.3%) stopped treatment due to progressive disease. 213 
 214 
 215 
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(iv) Survival and prognostic factor analysis 216 
Survival analysis revealed that median PFS in the uterine patients was 3 217 
months (95% CI 2.5-4.7) compared to 4.5 months (3.7-5.1) in the non-uterine 218 
STS population. Median OS was 17.5 months (95% CI 11.1 – 19.6) compared 219 
to 11 months (10.2-12.9), p=0.352 and was not statistically significant. The 220 
corresponding hazard ratio and confidence interval based on the Cox 221 
proportional hazards model is 0.84 (0.59, 1.21) for uterine versus other.   222 
Survival curves are shown in Figure 2 (a) and (b)  223 
Survival analysis was also performed for uterine versus non-uterine sarcoma 224 
in women, and uterine LMS versus LMS of other origin and there was no 225 
statistically significant difference in median PFS duration and OS duration for 226 
either group. Survival analysis for all males versus all females treated with 227 
pazopanib showed significantly longer PFS in women (4.60 months (95% CI 228 
3.65-5.29) versus 3.94 months in men (2.76-4.67) p=0.032) and also OS 229 
(14.13 months ( (95% CI 10.97, 17.15) versus 10.38 in men ( 8.02-230 
11.66)p=0.018) 231 
In addition a comparison was made between the uterine sarcoma patients on 232 
the PALETTE study treated with pazopanib compared to those randomised to 233 
placebo. Median PFS duration in the pazopanib arm was 2.99 months (95% 234 
CI 2.53, 4.67) versus 0.82 months in placebo arm (0.72, 1.02) p=0.000. 235 
Median OS duration in the pazopanib arm was 17.45 months (95% CI, 11.14, 236 
19.61) versus 7.92 months (1.12, 14.82) p=0.038. The response rate of 237 
patients with uterine sarcoma to pazopanib in PALETTE was 11.4% versus 238 
0.0% to placebo. 239 
 240 
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Prognostic factor analysis was performed. Due to the small overall number of 241 
patients with uterine sarcoma it was not possible to perform a multivariate 242 
analysis. Univariate prognostic factor analysis was performed for best overall 243 
response, PFS and OS, looking at the role of age, performance status, tumour 244 
grade and the presence or absence of lung, liver and bone metastases. None 245 
of these prognostic factors were found to be significant. 246 
 247 
(v) Post protocol treatments 248 
The majority of patients (n=41, 91%) received further lines of treatment as 249 
summarized in Table 3. Follow-up chemotherapy was the most frequently 250 
offered treatment provided to uterine sarcoma patients on disease 251 
progression (65.9%) radiotherapy was the second most frequent treatment 252 
(26.8%). 253 
 254 
 255 
Discussion 256 
This pooled analysis involving data from two large EORTC/GSK jointly 257 
sponsored studies has shown that patients with uterine sarcoma (the vast 258 
majority of whom had uterine LMS) have comparable outcomes to pazopanib 259 
to those of the non-uterine STS population, with similar toxicity profiles. It is 260 
notable that many of the uterine patients (61%) who took part in the PALETTE 261 
study received treatment in the ≥ 2nd line setting, a reflection of the number of 262 
treatment options available for this group. Also more patients in the uterine 263 
group were of performance status 1, than 0 compared to the non-uterine 264 
sarcoma population treated with pazopanib and more had higher grade 265 
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tumours. The response rate to pazopanib was 11.4% with a median PFS of 3 266 
months, which is similar to other drugs active in uterine LMS such as 267 
doxorubicin (1st line RR 14%, PFS 4.6 months, all STS, Judson et al (19)), 268 
gemcitabine and docetaxel (1st line LMS, RR 25%, PFS 7.1 months Seddon et 269 
al (20)), gemcitabine and docetaxel (pre treated LMS, RR 53%, median time 270 
to progression  5.6 months, Hensley et al ( 21)) , single agent gemcitabine ( 271 
metastatic STS, RR 8%, PFS 3.0 months Maki et al (22), trabectedin (RR 272 
10% uterine LMS median PFS 5.8 months Monk et al (23)) and dacarbazine 273 
(previously treated STS overall RR 4%, PFS 2 months Garcia del Muro et al 274 
(24)).with the caveat that these studies cannot be meaningfully compared due 275 
to selection bias and differing patient populations.  276 
The additional analyses performed have shown interesting insights. The fact 277 
that those patients with uterine LMS in the PALETTE study did significantly 278 
better than those with uterine LMS treated with placebo is unsurprising.  There 279 
was no significant in difference in response to pazopanib between female 280 
patients with uterine sarcomas and females with non uterine sarcomas, nor 281 
was there a difference between those with uterine LMS and non uterine LMS. 282 
However overall female patients that were treated with pazopanib fared better 283 
than their male counterparts. 284 
Pazopanib is the first tyrosine kinase inhibitor that has been approved both in 285 
Europe and the US for treatment of advanced non-adipocytic STS. It is a 286 
multi-targeted drug acting through VEGFR 1-3, PDGFR and KIT.  The main 287 
mode of action of pazopanib in STS, both uterine and non-uterine STS is still 288 
not fully elucidated and further work is needed in order to identify those 289 
patients most likely to benefit. Apart from its suggested role as an 290 
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angiogenesis inhibitor, targeting VEGF receptors, PDGFR receptors are likely 291 
to be an important target in STS. The role of PDGFR-α in uterine sarcomas 292 
has been explored previously. Expression of PDGFR-α has been 293 
demonstrated in 60% of uterine LMS samples by immunohistochemistry (IHC) 294 
(25). A second study showed strong staining by IHC for PDGFR-α in 70% of 295 
uterine LMS samples (26). A recent analysis of 349 patient samples of uterine 296 
LMS showed significant overexpression of PDGFR- α (p<0.0001) and-ß 297 
(p<0.0127) compared to non-neoplastic controls. Furthermore VEGF was 298 
over-expressed in metastatic tumours when compared to primary tumours 299 
strengthening the rationale for drugs targeting these pathways. (27) 300 
It is interesting to speculate whether response rates might have been higher if 301 
pazopanib had been used in an earlier treatment line and in a greater 302 
percentage of patients with a performance status of 0. Furthermore, the 303 
relationship between pazopanib and tumour grade is intriguing. Many more 304 
uterine sarcoma patients included were classified as high grade (84.1%) 305 
compared to the non-uterine population (54.8%). Both the PALETTE study 306 
and a separately published analysis of long term responders to pazopanib has 307 
revealed it was those with low or intermediate grade tumours and in addition 308 
those with performance status 0 that had the longest duration of pazopanib 309 
treatment (28). A possible future option would be to investigate the response 310 
of those patients with low grade uterine LMS or ESS to pazopanib. The non-311 
significant trend towards improved OS for uterine sarcoma patients in this 312 
analysis compared to the advanced non-uterine STS population could 313 
possibly be explained by the widespread use of post protocol treatments 314 
including chemotherapy, radiotherapy and surgery and is indicative of  the 315 
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greater number of treatment options for uterine LMS. However there is 316 
insufficient information on subsequent treatments available to investigate 317 
whether this correlates with overall survival. 318 
Thus far systemic treatment of advanced high grade uterine sarcoma 319 
has relied on a range of cytotoxic treatments; whilst hormonal strategies play 320 
a role in the management of low grade hormone receptor positive LMS and 321 
ESS.  Currently single agent doxorubicin remains the standard of care in the 322 
first line metastatic setting for those patients with uterine LMS . Data 323 
presented at ASCO 2015 of the randomised UK GEDDiS trial has shown that 324 
doxorubicin has superior outcomes compared to gemcitabine docetaxel in the 325 
first line and is better tolerated with less toxicity. Beyond first line gemcitabine 326 
in single agent or in combination with docetaxel, and also trabectedin are 327 
active and pazopanib can now be considered as an additional option.  Modest 328 
response rates and survival outcomes to systemic treatment highlight the poor 329 
prognosis of the uterine sarcoma population and clearly underline the urgent 330 
requirement for innovative new strategies involving novel compounds in this 331 
patient group. These two large trials with pazopanib in STS and their 332 
subsequent pooled analyses represent the considerable recruitment ability of 333 
the EORTC and the centres involved and underline the importance of ongoing 334 
international collaboration in order to make meaningful progress in such rare 335 
tumour types. 336 
 337 
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Table/Figure legends 345 
Table 1 patient characteristics 346 
This table describes demographic details of the patients included in the 347 
analysis. 348 
 
Site of primary 
Other (N = 
299) 
Uterine (N 
= 44) 
Total (N = 
343) 
N (%) N (%) N (%) 
Age at trial entry (years) 
Median 54 55 54 
Range 18–83 33–79 18–83 
Q1–Q3 38–63 51–67 40–64 
Age at trial entry 
≤40 84 (28.1) 2 (4.5) 86 (25.1) 
40–50 46 (15.4) 9 (20.5) 55 (16.0) 
50–70 139 (46.5) 26 (59.1) 165 (48.1) 
>70 30 (10.0) 7 (15.9) 37 (10.8) 
Sex 
Male 147 (49.2) 0 (0.0) 147 (42.9) 
Female 152 (50.8) 44 (100.0) 196 (57.1) 
Performance status 
0 153 (51.2) 18 (40.9) 171 (49.9) 
1 146 (48.8) 26 (59.1) 172 (50.1) 
Histology (central review) 
Leiomyosarcoma 95 (31.8) 39 (88.6) 134 (39.1) 
Synovial 
sarcoma 
62 (20.7) 0 (0.0) 62 (18.1) 
Other 142 (47.5) 5 (11.4) 147 (42.8) 
Tumour grade (central review) 
Low 27 (9.0) 1 (2.3) 28 (8.2) 
Intermediate 106 (35.5) 6 (13.6) 112 (32.7) 
High 164 (54.8) 37 (84.1) 201 (58.6) 
Unknown 2 (0.7) 0 (0.0) 2 (0.6) 
Extent of disease at entry (non-
cumulative) 
Primary (uterus) 85 (28.4) 6 (13.6) 91 (26.5) 
Lymph node 60 (20.1) 6 (13.6) 66 (19.2) 
Lung 238 (79.6) 32 (72.7) 270 (78.7) 
Liver 82 (27.4) 11 (25.0) 93 (27.1) 
Bone 40 (13.4) 12 (27.3) 52 (15.2) 
Prior lines of systemic therapy 
for advanced disease 
0 39 (13.0) 5 (11.4) 44 (12.8) 
1 138 (46.2) 12 (27.3) 150 (43.7) 
≥2 122 (40.8) 27 (61.3) 105 (43.5) 
349 
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Table 2:  Grade 3 and 4 toxicities 350 
The table below compares the occurrence of Common Toxicity Criteria Grade 351 
3-4 events across the patient groups. The overview is limited to those 352 
toxicities reported as grade 3-4 in at least 5% of the overall patient population, 353 
but also summarizes the number of any grade 3-4 event across the patient 354 
groups. 355 
 356 
Hematological and 
biochemistry events 
Site of primary 
Other (N = 299) Uterine (N = 44) Total (N = 343) 
N (%) N (%) N (%) 
Lymphopenia 36 (12.0) 5 (11.4) 41 (12.0) 
Anemia 19 (6.4) 2 (4.5) 21 (6.1) 
ASAT 18 (6.0) 3 (6.8) 21 (6.1) 
ALAT 24 (8.0) 2 (4.5) 26 (7.6) 
Hypertension 20 (6.7) 2 (4.5) 22 (6.4) 
Fatigue 43 (14.4) 4 (9.1) 47 (13.7) 
Diarrhea 19 (6.4) 1 (2.3) 20 (5.8) 
Infection without neutropenia 23 (7.7) 0 (0.0) 23 (6.7) 
Tumour pain 27 (9.0) 5 (11.4) 32 (9.3) 
Other pain 27 (9.0) 5 (11.4) 32 (9.3) 
Dyspnea 19 (6.4) 2 (4.5) 21 (6.1) 
Any Grade 3–4 event 202 (67.6) 28 (63.6) 230 (67.1) 
 357 
358 
 19 
Table 3 post protocol therapy 359 
This table details treatments received by patients following treatment with 360 
pazopanib. 361 
1
 Immunotherapy, Embolization (5), TACE, Sterile Compound C31510 as part of the CR0510 protocol 362 
(NCT01251562), Zometa, Sunitinib 363 
2
 Sunitinib (1) , Sorafenib (1), Everolimus(1) 364 
3
 Zometa and a phosphoinoside 3-kinase GSK inhibitor as part of a phase I dose escalation study,  365 
 366 
Number of post 
protocol therapies — 
patients off protocol 
treatment 
Site of primary 
Other (N = 269) Uterine (N = 41) Total (N = 310) 
N (%) N (%) N (%) 
Chemotherapy 139 (51.7) 27 (65.9) 166 (53.5) 
Targeted therapy 21 (7.8) 3(7.3)2 25 (8.1) 
Radiotherapy 51 (19.0) 11 (26.8) 62 (20.0) 
Surgery 19 (7.1) 9 (22.0) 28 (9.0) 
Other therapy 10 (3.7)1 2 (4.9)3 12 (3.9) 
 367 
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Figure 1 Consort diagram 368 
 369 
370 
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Figure 2 (a) PFS by site of origin 371 
Kaplan Meier survival curve showing progression free survival by site of origin 372 
 373 
374 
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Figure 2 (b) OS by site of origin 375 
Kaplan Meier survival curve showing overall survival by site of origin 376 
 377 
378 
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